IL304611A - gcn2-modulating compounds and uses thereof - Google Patents
gcn2-modulating compounds and uses thereofInfo
- Publication number
- IL304611A IL304611A IL304611A IL30461123A IL304611A IL 304611 A IL304611 A IL 304611A IL 304611 A IL304611 A IL 304611A IL 30461123 A IL30461123 A IL 30461123A IL 304611 A IL304611 A IL 304611A
- Authority
- IL
- Israel
- Prior art keywords
- gcn2
- modulating compounds
- modulating
- compounds
- gcn2 modulating
- Prior art date
Links
- 101150033008 EIF2AK4 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Holo Graphy (AREA)
- Liquid Crystal Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL304611A true IL304611A (en) | 2023-09-01 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304611A IL304611A (en) | 2021-01-22 | 2023-07-20 | gcn2-modulating compounds and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083897A1 (enExample) |
| EP (1) | EP4281182A1 (enExample) |
| JP (1) | JP2024504364A (enExample) |
| KR (1) | KR20240021143A (enExample) |
| CN (1) | CN117203206A (enExample) |
| AU (1) | AU2022210760A1 (enExample) |
| BR (1) | BR112023014723A2 (enExample) |
| CA (1) | CA3209124A1 (enExample) |
| CO (1) | CO2023010940A2 (enExample) |
| CR (1) | CR20230408A (enExample) |
| IL (1) | IL304611A (enExample) |
| MX (1) | MX2023008589A (enExample) |
| PE (1) | PE20240691A1 (enExample) |
| WO (1) | WO2022159746A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| WO2023230567A1 (en) * | 2022-05-25 | 2023-11-30 | Hibercell, Inc. | Gcn2 modulator for treating cancer |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| IL322199A (en) * | 2023-01-20 | 2025-09-01 | Hibercell Inc | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3-sulfonamido)-6,2-difluorophenyl)-N-methylimidazo[1, 5-A]pyrazine-1-carboxamide and methods of use are |
| WO2025122985A1 (en) * | 2023-12-08 | 2025-06-12 | Hibercell, Inc. | Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004279427B2 (en) * | 2003-10-08 | 2008-07-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ES2422263T3 (es) * | 2008-12-19 | 2013-09-10 | Nerviano Medical Sciences Srl | Pirazoles bicíclicos como inhibidores de la proteinquinasa |
| HRP20241768T1 (hr) * | 2016-08-10 | 2025-02-28 | Takeda Pharmaceutical Company Limited | Heterociklički spoj |
| JP7229257B2 (ja) * | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| US20220388964A1 (en) * | 2019-04-12 | 2022-12-08 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| JP2023514328A (ja) * | 2020-02-17 | 2023-04-05 | アレスタ・セラピューティクス・ベスローテン・フェンノートシャップ | Ｇｃｎ２モジュレーター化合物 |
-
2022
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504364A (ja) | 2024-01-31 |
| KR20240021143A (ko) | 2024-02-16 |
| CA3209124A1 (en) | 2022-07-28 |
| CO2023010940A2 (es) | 2023-12-11 |
| CN117203206A (zh) | 2023-12-08 |
| BR112023014723A2 (pt) | 2023-10-03 |
| US20240083897A1 (en) | 2024-03-14 |
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| WO2022159746A1 (en) | 2022-07-28 |
| AU2022210760A1 (en) | 2023-09-07 |
| MX2023008589A (es) | 2023-08-09 |
| PE20240691A1 (es) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304611A (en) | gcn2-modulating compounds and uses thereof | |
| IL296357B1 (en) | Heterocyclic pyrimido compounds and their uses | |
| IL276095A (en) | gcn2 inhibitors and their uses | |
| IL314812A (en) | KRAS modulators and their uses | |
| EP4096651A4 (en) | COMPOUNDS AND THEIR USES | |
| EP4096664A4 (en) | COMPOUNDS AND USES THEREOF | |
| EP4096668A4 (en) | COMPOUNDS AND USES THEREOF | |
| EP4247815A4 (en) | COMPOUNDS AND USES THEREOF | |
| IL304222A (en) | Alternative pyridotriazine compounds and their uses | |
| HUE071494T2 (hu) | Vegyületek és eljárások az UBE3A-ATS modulálására | |
| SI4117784T1 (sl) | Gpr52 modulatorne spojine | |
| IL310811A (en) | Compounds and Methods for Modulating SCN1A Expression | |
| IL298860B1 (en) | GCN 2 inhibitor compounds, compositions containing them and uses thereof | |
| GB202004094D0 (en) | New compounds and uses | |
| SI4401833T1 (sl) | Gpr52-modulatorne spojine | |
| SI4136092T1 (sl) | Spojine in postopki za moduliranje izražanja angiotenzinogena | |
| EP4337211A4 (en) | COMPOUNDS AND THEIR USES | |
| IL301007B1 (en) | GPR52 modulator compounds | |
| HK40104241A (zh) | Gcn2调节化合物及其用途 | |
| GB202105483D0 (en) | Compounds and uses thereof | |
| HK40093600A (en) | Thienopyrimidinedione compounds and application thereof | |
| GB202102243D0 (en) | New compounds and uses | |
| HK40091358A (en) | Compounds and methods for modulating plp1 | |
| HK40111947A (en) | Egfr-cmet-targeted compounds and uses thereof | |
| HK40061966A (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin |